Global Code Comparison · 2020-07-02 · About this Global Code Comparison This Global Code Comparison table, initiated by IFPMA’s Ethics & Business Integrity Committee (eBIC),

Global Code ComparisonA snapshot of IFPMA’s member associations’ self-regulation mechanisms

July 2020

Index

About this Global Code Comparison

1. Code Applicability and General Information

2. Types of Interactions Covered

3. Types of Products Covered

4. Types of Provisions/Practices Covered

5. Transparency & Disclosure

6. Complaint Handling Provisions

IFPMA - Global Code Comparison 2020

2/12

About this Global Code ComparisonThis Global Code Comparison table, initiated by

IFPMA’s Ethics & Business Integrity Committee

(eBIC), is the collective feedback of IFPMA member

associations and provides a general overview of

national and regional associations’ codes and their

related provisions. All associations’ input in this

comparison is based on data collected between

April – June 2020. This comparison table is a

snapshot of the global research-based pharmaceutical

industry’s self-regulation mechanisms and the

commitment of IFPMA members to the ethical

promotion of medicines and interactions with

healthcare professionals, patient organizations and

medical institutions, for the safety and benefit of

patients worldwide.

It should be noted that the intention of this table is

not to provide a comprehensive analysis of regional

and national associations’ codes. Therefore, the

comparison table does not include a precise account

of national codes’ requirements, depth of coverage or

additional provisions. The Yes/No answers provided

in this comparison simply indicate whether or not a

certain provision is, or is not, covered by the relevant

code in question as benchmarked to the global IFPMA

Code of Practice.

For detailed information relating to provisions in

specific countries, please refer to the respective

national codes, which can be accessed on the

IFPMA website.


3/12

For the 2020 edition particular attention was paid to the IFPMA Ethos, which has been developed to facilitate the shift from a rules-based approach to a Code based on values and principles.

This chart represents the number of member associations that integrated the Ethos in their code, it does not include those associations that did not provide data.

The information provided is based on the survey answers submitted by the respective IFPMA member associations.

s

Educ

atio

n

Privacy

o y

Speaking Up

Transparency

r

Inno

vatio

n

Quality

F ir

Integrity

AccountabilityAct with integrity and honesty to improve patient

care and build trust with those we serve and to

respect the independence of healthcare providers, patients

and other stakeholders.

42

6

Ethos integrated in Code Ethos not integrated in Code

Country

Affiliation

When did your fi

rst Co

de beco

me

effect

ive / w

hen was it fi

rst en

forced?

When did your la

test C

ode revi

sion

become e

ffectiv

e?

Does your C

ode apply t

o

non-mem

bers?

Does your C

ode inclu

de the v

alues

reflect

ive

of the IF

PMA Ethos?

Does your as

sociatio

n offer

a Code o

f Ethics

training?

Do you en

gage with

exter

nal stak

eholders fo

r

consultatio

n regard

ing potentia

l Code r

evisio

ns 1 Code Applicability and General Information


Global Global IFPMA 1981 2019 No Yes Yes YesCentral America Regional

Central America and the Dominican Republic

Fedefarma 2006 2019 No Yes No Yes

Europe Regional Europe EFPIA 1992 2019 Yes Yes Yes YesLatin America Regional

Latin America FIFARMA 2014 2020 No Yes No Yes

Americas

Argentina CAEMe 2007 2018 No No No NoBrazil INTERFARMA 2008 2016 Yes Yes Yes YesCanada IMC 1988 2019 No Yes Yes YesChile CIF 2006 2019 No Yes Yes YesColombia AFIDRO 2005 2020 No Yes No YesEcuador IFI 1986 2019 No Yes No YesMéxico AMIIF/CETIFARMA 2005 2013 No Yes Yes YesPeru ALAFARPE 2016 2019 No Yes No YesUnited States PhRMA 2002 2019 No Yes No No

Asia Pacific

Australia Medecines Australia 1960 2019 Yes Yes Yes YesChina PhIRDA 2018 2018 No Yes Yes NoChina RDPAC 1999 2019 No Yes Yes YesChinese Taipei IRPMA 2003 2019 Yes Yes Yes YesHong Kong HKAPI 1970 2019 Yes Yes Yes YesIndia OPPI 2012 2020 No No No NoIndonesia IPMG 2001 2019 No Yes Yes NoJapan JPMA 1976 2019 No Yes Yes YesKorea KPBMA 1994 2017 No No Yes YesKorea KRPIA 2009 2017 No Yes No YesPhilippines PHAP 2000 2019 No Yes Yes YesSingapore SAPI 2010 2020 No Yes Yes YesThailand PReMA 1986 2019 No Yes No Yes

Europe

Austria PHARMIG 1970 2020 Yes Yes Yes YesBelarus AIPM 2009 2019 No Yes Yes YesBelgium pharma.be 1976 2020 No Yes No YesBosnia Herzegovina AIPM BH 2019 2019 No Yes No NoDenmark Lif/ENLI 1973 2020 Yes Yes No YesFinland PIF 1959 2019 No No Yes YesFrance LEEM 2011 2019 No Yes No YesGeorgia APCRG 2014 2019 Yes Yes No NoGermany vfa/FSA 2004 2020 No Yes No YesItaly FARMINDUSTRIA 1990 2019 No No No NoNetherlands Association

Innovative Medicines1999 2019 Yes Yes Yes Yes

Norway LMI 1975 2020 No Yes Yes YesPortugal APIFARMA 1987 2018 No No Yes YesRussian Federation AIPM 1998 2019 No Yes Yes YesSpain FARMAINDUSTRIA 1991 2016 Yes Yes Yes YesSweden LIF 1969 2020 No Yes Yes YesSwitzerland Interpharma/

scienceindustries1969 2020 Yes Yes Yes Yes

Turkey AIFD 2003 2019 No Yes Yes YesUkraine AIPM 2018 2019 No Yes No YesUnited Kingdom ABPI/PMCPA 1958 2019 Yes Yes Yes No

Middle East & Africa

Ghana AREPI 2019 Pending Yes Yes Yes YesKenya KAPI 2016 2019 No Yes Yes YesSouth Africa IPASA/MCA 2012 2019 No Yes No Yes

No data received from BAPI (Bangladesh) and PhAMA (Malaysia). 4/12

Country

Affiliation

Patient O

rganizatio

ns

Patient as

Individuals

/Caregive

rs

Government O

fficials/

Public Officia

ls

Medical in

stitutio

ns

Healthcar

e Profes

sionals

Which are

the r

elevan

t types

of inter

actions

between

member

companies an

d stakeh

olders

that are

covered in yo

ur Code?

2 Types of Interactions Covered


Does your as

sociatio

n have an

y additio

nal codes

or guidance

regard

ing interact

ions with

other

stakeh

olders (su

ch as distr

ibutors, supplier

s)?

Global Global IFPMA Yes Yes Yes No No NoCentral America Regional


Fedefarma Yes Yes Yes Yes Yes No

Europe Regional Europe EFPIA Yes Yes Yes No Yes NoLatin America Regional

Latin America FIFARMA Yes Yes Yes Yes Yes No

Americas

Argentina CAEMe Yes No Yes Yes Yes NoBrazil INTERFARMA Yes Yes Yes Yes Yes YesCanada IMC Yes Yes Yes Yes Yes NoChile CIF Yes No No No No YesColombia AFIDRO Yes Yes Yes No Yes NoEcuador IFI Yes Yes Yes Yes Yes NoMéxico AMIIF/CETIFARMA Yes Yes Yes Yes Yes YesPeru ALAFARPE Yes Yes Yes Yes Yes NoUnited States PhRMA Yes No No No No No

Asia Pacific

Australia Medecines Australia Yes Yes Yes Yes Yes NoChina PhIRDA Yes Yes Yes No Yes NoChina RDPAC Yes No No No No NoChinese Taipei IRPMA Yes Yes Yes Yes Yes NoHong Kong HKAPI Yes Yes Yes No No NoIndia OPPI Yes Yes Yes No Yes NoIndonesia IPMG Yes Yes No No Yes NoJapan JPMA Yes Yes Yes Yes Yes NoKorea KPBMA Yes Yes Yes No No YesKorea KRPIA Yes Yes No No Yes NoPhilippines PHAP Yes Yes Yes Yes Yes NoSingapore SAPI Yes Yes Yes No Yes NoThailand PReMA Yes Yes Yes No No No

Europe

Austria PHARMIG Yes Yes Yes No No YesBelarus AIPM Yes Yes Yes Yes Yes NoBelgium pharma.be Yes Yes Yes No No NoBosnia Herzegovina AIPM BH Yes Yes Yes No Yes NoDenmark Lif/ENLI Yes Yes Yes No Yes NoFinland PIF Yes Yes Yes Yes Yes NoFrance LEEM Yes No Yes Yes No NoGeorgia APCRG Yes Yes Yes Yes Yes NoGermany vfa/FSA Yes No No No No YesItaly FARMINDUSTRIA Yes No No No No NoNetherlands Association

Innovative MedicinesYes Yes Yes Yes No Yes

Norway LMI Yes Yes Yes Yes Yes NoPortugal APIFARMA Yes Yes Yes No No NoRussian Federation AIPM Yes Yes Yes Yes No NoSpain FARMAINDUSTRIA Yes Yes Yes Yes Yes YesSweden LIF Yes Yes Yes Yes Yes NoSwitzerland Interpharma/

scienceindustriesYes Yes Yes No Yes No

Turkey AIFD Yes Yes Yes Yes No NoUkraine AIPM Yes Yes Yes Yes No YesUnited Kingdom ABPI/PMCPA Yes Yes Yes Yes Yes Yes


Ghana AREPI Yes Yes Yes No Yes NoKenya KAPI Yes Yes Yes Yes Yes YesSouth Africa IPASA/MCA Yes Yes Yes Yes No No

5/12No data received from BAPI (Bangladesh) and PhAMA (Malaysia).

Country

Affiliation

Medical D

evices

Over-th

e-counter

(OTC)

Medicines

Generics

RxD Pharmace

uticals

Which products

are co

vered by

your C

ode?

3 Types of Products Covered


Global Global IFPMA Yes Yes No YesCentral America Regional


Fedefarma Yes Yes Yes Yes

Europe Regional Europe EFPIA Yes Yes No NoLatin America Regional

Latin America FIFARMA Yes Yes Yes Yes

Americas

Argentina CAEMe Yes Yes No YesBrazil INTERFARMA Yes Yes No YesCanada IMC Yes No No NoChile CIF Yes No No NoColombia AFIDRO Yes Yes No NoEcuador IFI Yes No No YesMéxico AMIIF/CETIFARMA Yes Yes Yes NoPeru ALAFARPE Yes No No NoUnited States PhRMA Yes No No No

Asia Pacific

Australia Medecines Australia Yes Yes No YesChina PhIRDA Yes Yes Yes YesChina RDPAC Yes Yes No NoChinese Taipei IRPMA Yes No No NoHong Kong HKAPI Yes Yes Yes YesIndia OPPI Yes Yes No NoIndonesia IPMG Yes Yes No NoJapan JPMA Yes No No NoKorea KPBMA Yes Yes No YesKorea KRPIA Yes No No YesPhilippines PHAP Yes Yes Yes YesSingapore SAPI Yes No No YesThailand PReMA Yes No No Yes

Europe

Austria PHARMIG Yes Yes No YesBelarus AIPM Yes Yes Yes YesBelgium pharma.be Yes No No YesBosnia Herzegovina AIPM BH Yes Yes Yes YesDenmark Lif/ENLI Yes Yes No YesFinland PIF Yes Yes No YesFrance LEEM No Yes No YesGeorgia APCRG Yes Yes No YesGermany vfa/FSA Yes No No NoItaly FARMINDUSTRIA Yes No No NoNetherlands Association

Innovative MedicinesYes Yes No Yes

Norway LMI Yes Yes No YesPortugal APIFARMA Yes Yes Yes YesRussian Federation AIPM Yes Yes No YesSpain FARMAINDUSTRIA Yes Yes No NoSweden LIF Yes Yes No YesSwitzerland Interpharma/

scienceindustriesYes Yes No Yes

Turkey AIFD Yes Yes No NoUkraine AIPM Yes Yes Yes NoUnited Kingdom ABPI/PMCPA Yes Yes No No


Ghana AREPI Yes Yes Yes YesKenya KAPI Yes Yes No YesSouth Africa IPASA/MCA Yes Yes Yes Yes


Country

Affiliation

Promotional A

ctivitie

s

Which provis

ions / prac

tices a

re

covered by

your C

ode?

Non-inter

ventio

nal Studies

/

Post-mark

eting Surve

illance

Off-label U

se

Clinica

l Use

Market

Researc

h

Patient S

upport Program

s (PSP)

Pre-approval

Communica

tion

Direct-

to-consumer A

dvertisi

ng

Non-promotional A

ctivitie

s

4 Types of Provisions/Practices Covered (1/3)


Global Global IFPMA Yes Yes No Yes Yes Yes Yes No YesCentral America Regional


Fedefarma Yes Yes Yes Yes Yes Yes Yes Yes Yes

Europe Regional Europe EFPIA Yes Yes No No No No Yes No NoLatin America Regional

Latin America FIFARMA Yes Yes Yes Yes Yes Yes Yes Yes Yes

Americas

Argentina CAEMe Yes No No No Yes Yes No Yes YesBrazil INTERFARMA Yes Yes Yes No Yes No No No YesCanada IMC Yes Yes No Yes Yes Yes Yes Yes YesChile CIF Yes Yes No No No No No Yes NoColombia AFIDRO Yes Yes No No Yes Yes No Yes YesEcuador IFI Yes Yes No Yes Yes Yes No Yes NoMéxico AMIIF/CETIFARMA Yes Yes Yes Yes Yes Yes Yes Yes NoPeru ALAFARPE Yes Yes Yes Yes Yes Yes Yes Yes YesUnited States PhRMA Yes Yes No No No No No No No

Asia Pacific

Australia Medecines Australia Yes Yes Yes Yes Yes No No Yes YesChina PhIRDA Yes Yes Yes Yes Yes Yes Yes No YesChina RDPAC Yes No No Yes Yes Yes Yes Yes YesChinese Taipei IRPMA Yes Yes Yes Yes Yes Yes Yes Yes YesHong Kong HKAPI Yes Yes No Yes Yes Yes Yes No YesIndia OPPI Yes Yes Yes Yes Yes Yes Yes Yes YesIndonesia IPMG Yes Yes No Yes Yes Yes Yes No YesJapan JPMA Yes Yes Yes Yes Yes Yes Yes No YesKorea KPBMA Yes Yes No Yes Yes Yes Yes Yes YesKorea KRPIA Yes Yes No No No No Yes No YesPhilippines PHAP Yes Yes Yes Yes Yes Yes Yes Yes NoSingapore SAPI Yes No No Yes Yes Yes No No NoThailand PReMA Yes No No Yes Yes Yes No No Yes

Europe

Austria PHARMIG Yes Yes Yes No No Yes Yes No YesBelarus AIPM Yes Yes Yes Yes Yes Yes Yes Yes YesBelgium pharma.be Yes Yes Yes Yes Yes No Yes No YesBosnia Herzegovina AIPM BH Yes Yes No Yes Yes Yes Yes Yes NoDenmark Lif/ENLI Yes Yes No Yes Yes No Yes No YesFinland PIF Yes Yes Yes Yes Yes Yes Yes Yes YesFrance LEEM Yes Yes Yes No No No Yes No NoGeorgia APCRG Yes Yes Yes Yes Yes Yes Yes No NoGermany vfa/FSA Yes Yes No No No Yes Yes Yes YesItaly FARMINDUSTRIA Yes No No No No Yes Yes Yes NoNetherlands Association

Innovative MedicinesYes Yes Yes Yes No No Yes Yes Yes

Norway LMI Yes Yes No No Yes No Yes Yes YesPortugal APIFARMA Yes No No No No Yes Yes No NoRussian Federation AIPM Yes Yes Yes No Yes No Yes Yes YesSpain FARMAINDUSTRIA Yes Yes Yes Yes Yes Yes Yes Yes YesSweden LIF Yes Yes Yes Yes Yes Yes Yes No YesSwitzerland Interpharma/

scienceindustriesYes Yes No Yes Yes Yes Yes Yes Yes

Turkey AIFD Yes Yes No Yes Yes Yes Yes Yes YesUkraine AIPM Yes Yes No Yes Yes Yes No No NoUnited Kingdom ABPI/PMCPA Yes Yes No Yes Yes Yes Yes Yes Yes


Ghana AREPI Yes Yes Yes Yes Yes Yes Yes Yes YesKenya KAPI Yes Yes Yes Yes Yes Yes Yes Yes YesSouth Africa IPASA/MCA Yes Yes Yes Yes Yes Yes Yes Yes Yes


Country

Affiliation

Medical Ed

ucation (w

ith

or with

out accre

ditatio

n)

Items o

f medica

l utility /

educational i

tems

Ban on cash

Fees fo

r Serv

ices

Ban on gifts

Travel

Sponsorship to

HCPs

Promotional a

ids

Samples



Global Global IFPMA Yes Yes Yes Yes Yes Yes Yes Yes YesCentral America Regional


Fedefarma Yes Yes Yes Yes Yes Yes Yes Yes Yes

Europe Regional Europe EFPIA Yes Yes Yes Yes Yes Yes Yes Yes YesLatin America Regional

Latin America FIFARMA Yes Yes Yes Yes Yes Yes Yes Yes Yes

Americas

Argentina CAEMe Yes Yes Yes Yes Yes Yes Yes Yes YesBrazil INTERFARMA Yes Yes Yes Yes Yes No Yes Yes YesCanada IMC Yes Yes Yes Yes Yes Yes Yes Yes YesChile CIF Yes Yes Yes Yes Yes Yes Yes Yes YesColombia AFIDRO Yes Yes Yes Yes Yes Yes Yes Yes YesEcuador IFI Yes Yes Yes Yes Yes Yes Yes Yes YesMéxico AMIIF/CETIFARMA Yes Yes Yes Yes Yes Yes Yes Yes YesPeru ALAFARPE Yes Yes Yes Yes Yes Yes Yes Yes YesUnited States PhRMA Yes Yes Yes Yes Yes Yes Yes Yes Yes

Asia Pacific

Australia Medecines Australia Yes Yes Yes Yes Yes Yes Yes Yes YesChina PhIRDA Yes Yes Yes Yes Yes Yes Yes Yes YesChina RDPAC Yes Yes Yes Yes Yes Yes Yes Yes YesChinese Taipei IRPMA Yes Yes Yes Yes Yes Yes Yes Yes YesHong Kong HKAPI Yes Yes Yes Yes Yes Yes Yes Yes YesIndia OPPI Yes Yes Yes Yes Yes Yes Yes Yes YesIndonesia IPMG Yes Yes Yes Yes Yes Yes Yes Yes YesJapan JPMA Yes Yes Yes Yes Yes Yes Yes Yes YesKorea KPBMA Yes Yes Yes Yes Yes Yes Yes Yes YesKorea KRPIA Yes Yes Yes Yes Yes Yes Yes Yes YesPhilippines PHAP Yes Yes Yes Yes Yes Yes Yes Yes YesSingapore SAPI Yes Yes Yes Yes Yes Yes Yes Yes YesThailand PReMA No Yes Yes Yes Yes Yes Yes Yes Yes

Europe

Austria PHARMIG Yes Yes Yes Yes Yes Yes Yes Yes YesBelarus AIPM Yes Yes Yes Yes Yes Yes Yes Yes YesBelgium pharma.be Yes Yes Yes Yes Yes Yes Yes Yes YesBosnia Herzegovina AIPM BH Yes Yes Yes Yes Yes Yes Yes Yes YesDenmark Lif/ENLI Yes Yes Yes Yes Yes Yes Yes Yes YesFinland PIF Yes Yes Yes Yes Yes Yes Yes Yes YesFrance LEEM Yes No Yes Yes Yes Yes Yes Yes YesGeorgia APCRG Yes Yes Yes Yes Yes Yes Yes Yes YesGermany vfa/FSA Yes Yes Yes Yes Yes Yes No Yes YesItaly FARMINDUSTRIA No No Yes Yes No Yes Yes Yes YesNetherlands Association

Innovative MedicinesYes Yes Yes Yes Yes Yes Yes Yes Yes

Norway LMI Yes Yes Yes Yes Yes Yes Yes Yes YesPortugal APIFARMA Yes No Yes Yes No Yes Yes Yes YesRussian Federation AIPM Yes Yes Yes Yes Yes Yes Yes Yes YesSpain FARMAINDUSTRIA Yes Yes Yes Yes Yes Yes Yes Yes YesSweden LIF Yes Yes Yes Yes Yes Yes Yes Yes YesSwitzerland Interpharma/

scienceindustriesYes Yes Yes Yes Yes Yes Yes Yes Yes

Turkey AIFD Yes Yes Yes Yes Yes Yes Yes Yes YesUkraine AIPM Yes Yes Yes Yes Yes Yes Yes Yes YesUnited Kingdom ABPI/PMCPA Yes Yes Yes Yes Yes Yes Yes Yes Yes


Ghana AREPI Yes Yes Yes Yes Yes Yes Yes Yes YesKenya KAPI Yes Yes Yes Yes Yes Yes Yes Yes YesSouth Africa IPASA/MCA Yes Yes Yes Yes Yes No Yes Yes Yes

8/12

Which provis

ions / prac

tices a

re

covered by

your C

ode?

No data received from BAPI (Bangladesh) and PhAMA (Malaysia).

Country

Affiliation

Events /

Hospitality

Funding (Gran

ts & Donati

ons)

Guidance on Valu

es

Guests /

Accompanyin

g Persons

Venue / Lo

cation

Ban on enter

tainment



Global Global IFPMA Yes Yes Yes Yes Yes NoCentral America Regional


Fedefarma Yes Yes Yes Yes Yes Yes

Europe Regional Europe EFPIA Yes Yes Yes Yes Yes YesLatin America Regional

Latin America FIFARMA Yes Yes Yes Yes Yes No

Americas

Argentina CAEMe Yes Yes Yes Yes Yes YesBrazil INTERFARMA Yes Yes Yes Yes Yes YesCanada IMC Yes Yes Yes Yes Yes NoChile CIF Yes Yes Yes Yes Yes YesColombia AFIDRO Yes Yes Yes Yes Yes YesEcuador IFI Yes Yes Yes Yes Yes YesMéxico AMIIF/CETIFARMA Yes Yes Yes Yes Yes YesPeru ALAFARPE Yes Yes Yes Yes Yes NoUnited States PhRMA Yes Yes Yes Yes Yes No

Asia Pacific

Australia Medecines Australia Yes Yes Yes Yes Yes NoChina PhIRDA Yes Yes Yes Yes Yes NoChina RDPAC Yes Yes Yes Yes Yes YesChinese Taipei IRPMA Yes Yes Yes Yes Yes NoHong Kong HKAPI Yes Yes Yes Yes Yes NoIndia OPPI Yes Yes Yes Yes Yes YesIndonesia IPMG Yes Yes Yes Yes Yes NoJapan JPMA Yes Yes Yes Yes Yes NoKorea KPBMA Yes Yes Yes Yes Yes NoKorea KRPIA Yes Yes Yes Yes Yes NoPhilippines PHAP Yes Yes Yes Yes Yes NoSingapore SAPI Yes Yes Yes Yes No NoThailand PReMA Yes Yes Yes Yes No No

Europe

Austria PHARMIG Yes Yes Yes Yes Yes YesBelarus AIPM Yes Yes Yes Yes Yes YesBelgium pharma.be Yes Yes Yes Yes Yes YesBosnia Herzegovina AIPM BH Yes Yes Yes Yes Yes YesDenmark Lif/ENLI Yes Yes Yes Yes Yes YesFinland PIF Yes Yes Yes Yes Yes YesFrance LEEM Yes Yes Yes Yes No YesGeorgia APCRG Yes Yes Yes Yes Yes YesGermany vfa/FSA Yes Yes Yes Yes Yes YesItaly FARMINDUSTRIA Yes Yes Yes Yes Yes YesNetherlands Association

Innovative MedicinesYes Yes Yes Yes Yes Yes

Norway LMI Yes Yes Yes Yes Yes YesPortugal APIFARMA Yes Yes No Yes Yes YesRussian Federation AIPM Yes Yes Yes Yes Yes NoSpain FARMAINDUSTRIA Yes Yes Yes Yes Yes YesSweden LIF Yes Yes Yes Yes Yes YesSwitzerland Interpharma/

scienceindustriesYes Yes Yes Yes Yes Yes

Turkey AIFD Yes Yes Yes Yes Yes YesUkraine AIPM Yes Yes Yes Yes Yes YesUnited Kingdom ABPI/PMCPA Yes Yes Yes Yes Yes Yes


Ghana AREPI Yes Yes Yes Yes Yes YesKenya KAPI Yes Yes Yes Yes Yes YesSouth Africa IPASA/MCA Yes Yes Yes Yes Yes Yes

9/12

Which provis

ions / prac

tices a

re

covered by

your C

ode?


Country

Affiliation

Transfe

r of va

lues to Pati

ent Organiza

tions

Transfe

r of va

lues to HCPs

Does your Co

de require

your m

embers

to disclose

the follo

wing?

5 Transparency & Disclosure


If your C

ode does

not require

any

of the d

isclosure

options, i

s there

national l

egislatio

n requirin

g any

of the o

ptions?

Transfe

r of va

lues to Medica

l

Institutio

ns/socie

ties?

Global Global IFPMA No No No N/ACentral America Regional


Fedefarma Yes Yes Yes N/A

Europe Regional Europe EFPIA Yes Yes Yes N/ALatin America Regional

Latin America FIFARMA Yes Yes Yes No

Americas

Argentina CAEMe No No No NoBrazil INTERFARMA No Yes Yes N/ACanada IMC No No No NoChile CIF No No No NoColombia AFIDRO No Yes No YesEcuador IFI No No No NoMéxico AMIIF/CETIFARMA No No No NoPeru ALAFARPE No Yes No N/AUnited States PhRMA No No No Yes

Asia Pacific

Australia Medecines Australia Yes Yes Yes N/AChina PhIRDA No No No NoChina RDPAC No No No YesChinese Taipei IRPMA Yes Yes Yes YesHong Kong HKAPI No No No NoIndia OPPI No No No NoIndonesia IPMG No No No NoJapan JPMA Yes Yes Yes N/AKorea KPBMA Yes Yes Yes N/AKorea KRPIA No No No YesPhilippines PHAP No No No YesSingapore SAPI No No No NoThailand PReMA No No No No

Europe

Austria PHARMIG Yes Yes Yes N/ABelarus AIPM No No No NoBelgium pharma.be Yes Yes Yes YesBosnia Herzegovina AIPM BH No No No NoDenmark Lif/ENLI No Yes Yes YesFinland PIF Yes Yes Yes N/AFrance LEEM Yes Yes Yes YesGeorgia APCRG No No No NoGermany vfa/FSA Yes Yes Yes N/AItaly FARMINDUSTRIA Yes Yes Yes NANetherlands Association

Innovative MedicinesYes Yes Yes N/A

Norway LMI Yes Yes Yes NoPortugal APIFARMA Yes Yes Yes YesRussian Federation AIPM Yes Yes Yes N/ASpain FARMAINDUSTRIA Yes Yes Yes NoSweden LIF Yes Yes Yes N/ASwitzerland Interpharma/

scienceindustriesYes Yes Yes N/A

Turkey AIFD Yes Yes Yes YesUkraine AIPM Yes Yes Yes N/AUnited Kingdom ABPI/PMCPA Yes Yes Yes N/A


Ghana AREPI Yes Yes Yes N/AKenya KAPI No No No NoSouth Africa IPASA/MCA No No No No


Country

Affiliation Do yo

u have a C

ode complain

t or

violati

on procedure i

n place?

In which ye

ar was

the proced

ure adopted

?

Can a complain

t be s

ubmitted an

onymously

?

Can members

submit a

complain

t?

Can non-mem

bers su

bmit a co

mplaint?

Can the g

eneral public

submit a co

mplaint?

Are complain

t deta

ils made a

vailab

le

to members

only?

Are complain

t details

made

availab

le public

ly?

6 Complaint Handling Provisions


Global Global IFPMA Yes 2006 Yes Yes Yes Yes No YesCentral America Regional


Fedefarma Yes 2006 No Yes Yes Yes Yes No

Europe Regional Europe EFPIA No N/A N/A N/A N/A N/A N/A N/ALatin America Regional

Latin America FIFARMA Yes 2014 Yes Yes Yes Yes Yes No

Americas

Argentina CAEMe Yes 2007 No Yes Yes No Yes NoBrazil INTERFARMA Yes 2008 No Yes Yes Yes Yes NoCanada IMC Yes 1988 No Yes Yes Yes Yes NoChile CIF Yes 2017 No Yes No No Yes NoColombia AFIDRO Yes 2019 Yes Yes Yes Yes No YesEcuador IFI Yes 2008 No Yes No No Yes NoMéxico AMIIF/CETIFARMA Yes 2006 No Yes Yes Yes Yes NoPeru ALAFARPE Yes 2016 No Yes No No Yes NoUnited States PhRMA No N/A N/A N/A N/A N/A N/A N/A

Asia Pacific

Australia Medecines Australia Yes 1960 No Yes Yes Yes No YesChina PhIRDA Yes 2018 No Yes Yes Yes Yes YesChina RDPAC Yes 2012 No Yes No No No NoChinese Taipei IRPMA Yes 2003 Yes N/A Yes Yes Yes NoHong Kong HKAPI Yes > 16 years No Yes Yes Yes Yes NoIndia OPPI Yes In Progress No Yes Yes Yes No NoIndonesia IPMG Yes 2001 No Yes Yes Yes Yes NoJapan JPMA Yes 2013 Yes Yes Yes Yes No NoKorea KPBMA Yes 2014 Yes Yes No No No NoKorea KRPIA Yes 2009 No Yes Yes Yes No NoPhilippines PHAP Yes 2000 Yes Yes No No Yes NoSingapore SAPI Yes Before 2010 No Yes Yes Yes Yes NoThailand PReMA Yes 2010 Yes Yes Yes Yes No Yes

Europe

Austria PHARMIG Yes 1970 Yes Yes N/A N/A Yes YesBelarus AIPM Yes 2019 No Yes Yes Yes Yes NoBelgium pharma.be Yes N/A No Yes Yes Yes Yes NoBosnia Herzegovina AIPM BH No N/A Yes Yes Yes Yes Yes NoDenmark Lif/ENLI Yes 1973 Yes Yes Yes Yes No YesFinland PIF Yes N/A Yes Yes Yes Yes No YesFrance LEEM Yes 2011 No Yes Yes Yes No NoGeorgia APCRG Yes 2014 No Yes Yes Yes Yes NoGermany vfa/FSA Yes 2004 Yes Yes Yes Yes No YesItaly FARMINDUSTRIA Yes 2004 No Yes Yes Yes Yes NoNetherlands Association

Innovative MedicinesYes 1999 Yes Yes Yes Yes No Yes

Norway LMI Yes 1975 Yes Yes Yes Yes No YesPortugal APIFARMA Yes 2015 Yes Yes Yes Yes Yes NoRussian Federation AIPM Yes 2007 No Yes Yes Yes Yes NoSpain FARMAINDUSTRIA Yes 2002 Yes Yes Yes Yes No YesSweden LIF Yes 1969 Yes Yes Yes Yes No YesSwitzerland Interpharma/

scienceindustriesYes 1969 No Yes Yes Yes Yes No

Turkey AIFD Yes 2004 Yes Yes Yes Yes Yes NoUkraine AIPM Yes 2019 No Yes Yes Yes Yes NoUnited Kingdom ABPI/PMCPA Yes 1958 Yes Yes Yes Yes No Yes


Ghana AREPI Yes 2019 Yes Yes Yes Yes No YesKenya KAPI Yes 2016 No Yes No Yes No YesSouth Africa IPASA/MCA Yes 2012 Yes Yes Yes Yes No No

11/12

If your as

sociatio

n has a C

ode

complaint p

rocedure

in place


Chemin des Mines 9 P.O. Box 195 1211 Geneva 20 Switzerland

www.ifpma.org

Documents

Global Code Comparison · 2020-07-02 · About this Global Code Comparison This Global Code Comparison table, initiated by IFPMA’s Ethics & Business Integrity Committee (eBIC),